Eton Pharmaceuticals, Inc. Cost of Revenue
Eton Pharmaceuticals, Inc. (ETON) reported Cost of Revenue of $12.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $12.18M, a 73.84% increase year-over-year.
- Eton Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $9.53M, a 28.43% increase year-over-year.
- Eton Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $8.18M, a 58.21% increase year-over-year.
- Eton Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $14.60M, a 263.10% increase year-over-year.
- Eton Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2025 was $37.21M, a 138.53% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2024 was $15.60M, a 47.43% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2023 was $10.58M, a 52.62% increase from fiscal 2022.
- Eton Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2022 was $6.93M, a 145.24% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.18M 10-Q · filed 2026-08-13 | $21.71M 10-Q · filed 2026-08-13 | $29.89M derived: sum of 3 quarters · filed 2026-08-13 | $44.49M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $9.53M 10-Q · filed 2026-05-14 | $17.71M derived: sum of 2 quarters · filed 2026-05-14 | $32.32M derived: sum of 3 quarters · filed 2026-05-14 | $39.32M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $8.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $22.79M derived: sum of 2 quarters · filed 2026-03-19 | $29.79M derived: sum of 3 quarters · filed 2026-08-13 | $37.21M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $14.60M 10-Q · filed 2025-11-06 | $21.61M derived: sum of 2 quarters · filed 2026-08-13 | $29.03M 10-Q · filed 2025-11-06 | $34.20M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $7.00M 10-Q · filed 2026-08-13 | $14.43M 10-Q · filed 2026-08-13 | $19.60M derived: sum of 3 quarters · filed 2026-08-13 | $23.62M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $7.42M 10-Q · filed 2026-05-14 | $12.59M derived: sum of 2 quarters · filed 2026-05-14 | $16.61M derived: sum of 3 quarters · filed 2026-05-14 | $20.06M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $9.19M derived: sum of 2 quarters · filed 2026-03-19 | $12.64M derived: sum of 3 quarters · filed 2026-03-19 | $15.60M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $4.02M 10-Q · filed 2025-11-06 | $7.47M derived: sum of 2 quarters · filed 2025-11-06 | $10.43M 10-Q · filed 2025-11-06 | $14.11M derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2024-06-30 | $3.45M 10-Q · filed 2025-08-07 | $6.41M 10-Q · filed 2025-08-07 | $10.09M derived: sum of 3 quarters · filed 2026-03-19 | $12.71M derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2024-03-31 | $2.96M 10-Q · filed 2025-05-13 | $6.64M derived: sum of 2 quarters · filed 2026-03-19 | $9.27M derived: sum of 3 quarters · filed 2026-03-19 | $11.58M derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2023-12-31 | $3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $6.31M derived: sum of 2 quarters · filed 2026-03-19 | $8.62M derived: sum of 3 quarters · filed 2026-03-19 | $10.58M 10-K · filed 2026-03-19 | |||
| 2023-09-30 | $2.63M 10-Q · filed 2024-11-12 | $4.94M derived: sum of 2 quarters · filed 2024-11-12 | $6.90M 10-Q · filed 2024-11-12 | $9.04M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2023-06-30 | $2.31M 10-Q · filed 2024-08-08 | $4.27M 10-Q · filed 2024-08-08 | $6.41M derived: sum of 3 quarters · filed 2025-03-18 | $7.61M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2023-03-31 | $1.96M 10-Q · filed 2024-05-09 | $4.10M derived: sum of 2 quarters · filed 2025-03-18 | $5.30M derived: sum of 3 quarters · filed 2025-03-18 | $8.04M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2022-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $3.34M derived: sum of 2 quarters · filed 2025-03-18 | $6.08M derived: sum of 3 quarters · filed 2025-03-18 | $6.93M 10-K · filed 2025-03-18 | |||
| 2022-09-30 | $1.20M 10-Q · filed 2023-11-09 | $3.95M derived: sum of 2 quarters · filed 2023-11-09 | $4.79M 10-Q · filed 2023-11-09 | $5.17M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-06-30 | $2.75M 10-Q · filed 2023-08-10 | $3.59M 10-Q · filed 2023-08-10 | $3.97M derived: sum of 3 quarters · filed 2024-03-14 | $4.62M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-03-31 | $849.00K 10-Q · filed 2023-05-11 | $718.00K 10-Q · filed 2022-05-12 | $1.22M derived: sum of 2 quarters · filed 2024-03-14 | $1.88M derived: sum of 3 quarters · filed 2024-03-14 | $2.05M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2021-12-31 | $372.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.03M derived: sum of 2 quarters · filed 2024-03-14 | $1.20M derived: sum of 3 quarters · filed 2024-03-14 | $2.83M 10-K · filed 2024-03-14 | |||
| 2021-09-30 | $654.00K 10-Q · filed 2022-11-10 | $828.00K derived: sum of 2 quarters · filed 2022-11-10 | $2.46M 10-Q · filed 2022-11-10 | $2.84M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2021-06-30 | $174.00K 10-Q · filed 2022-08-11 | $136.00K 10-Q · filed 2021-08-16 | $1.80M 10-Q · filed 2022-08-11 | $1.73M 10-Q · filed 2021-08-16 | $2.19M derived: sum of 3 quarters · filed 2023-03-16 | $2.33M derived: sum of 4 quarters · filed 2023-03-16 | |
| 2021-03-31 | $1.59M 10-Q · filed 2022-05-12 | $2.01M derived: sum of 2 quarters · filed 2023-03-16 | $2.16M derived: sum of 3 quarters · filed 2023-03-16 | $2.18M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2020-12-31 | $422.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $566.00K derived: sum of 2 quarters · filed 2023-03-16 | $594.00K derived: sum of 3 quarters · filed 2023-03-16 | $436.00K 10-K · filed 2023-03-16 | $286.00K 10-K · filed 2021-03-16 | ||
| 2020-09-30 | $144.00K 10-Q · filed 2020-11-12 | $172.00K derived: sum of 2 quarters · filed 2021-08-16 | $14.00K 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | $28.00K 10-Q · filed 2021-08-16 | $130.00K 10-Q · filed 2021-08-16 | |||||
| 2020-03-31 | $102.00K 10-Q · filed 2021-05-13 | ||||||
| 2019-12-31 | $453.00K 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |